26
|
Barkas F, Liberopoulos E, Ntekouan SF, Milionis H. Sodium-glucose transport protein 2 inhibitors and risk of incident stroke: A systematic review and meta-analysis. Atherosclerosis 2020. [DOI: 10.1016/j.atherosclerosis.2020.10.313] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
27
|
Rizos C, Liamis G, Skoumas I, Rallidis L, Tziomalos K, Skalides E, Kotsis V, Garoufi A, Athyros V, Kolovou G, Sfikas G, Bilianou E, Koutagiar I, Kiouri E, Agapakis D, Zacharis E, Antza C, Attilakos A, Katsiki N, Anagnostis P, Koumaras C, Liberopoulos E. Clinical characteristics of patients with familial hypercholesterolemia: Data from the HELLAS-FH registry. Atherosclerosis 2020. [DOI: 10.1016/j.atherosclerosis.2020.10.659] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
28
|
Rizos C, Liamis G, Skoumas I, Rallidis L, Tziomalos K, Skalides E, Kotsis V, Garoufi A, Athyros V, Kolovou G, Sfikas G, Bilianou E, Koutagiar I, Kiouri E, Agapakis D, Zacharis E, Antza C, Attilakos A, Katsiki N, Koumaras C, Liberopoulos E. Cholesterol levels of high-density lipoprotein (HDL-C), APOB/APOA1 ratio and cardiovascular risk in patients with familial hypercholesterolemia (FH): Data from the HELLAS-FH registry. Atherosclerosis 2020. [DOI: 10.1016/j.atherosclerosis.2020.10.127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
29
|
Rizos C, Skoumas I, Rallidis L, Tziomalos K, Skalides E, Kotsis V, Garoufi A, Athyros V, Kolovou G, Sfikas G, Bilianou E, Koutagiar I, Kiouri E, Agapakis D, Zacharis E, Antza C, Attilakos A, Katsiki N, Anagnostis P, Elisaf M, Liberopoulos E. Latest European guidelines for dyslipidemias in the setting of familial hypercholesterolemia: Data from the hellas-fh registry. Atherosclerosis 2020. [DOI: 10.1016/j.atherosclerosis.2020.10.131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
30
|
Rallidis L, Vlachopoulos C, Liberopoulos E, Skoumas I, Kiouri E, Koutagiar I, Anastasiou G, Kosmas N, Tousoulis D, Iliodromitis E. The new LDL-C target <55 mg/dL is achieved by less than 40% of very high risk patients with familial hypercholesterolaemia despite receiving PCSK9 inhibitors: real world data. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2999] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The recently published ESC/EAS guidelines for the management of dyslipidaemias have lowered the low-density lipoprotein cholesterol (LDL-C) target in the very high risk patients below 55 mg/dL.
Purpose
To examine how achievable is this target in very high risk patients receiving a proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) on top of lipid-lowering treatment (LLT).
Methods
The cohort comprised 158 patients who attended the lipid clinic of 3 hospitals in Greece and started treatment with PCSK9i. Patients were requested to attend the lipid clinic 3 months after the initiation of PCSK9i.
Results
Ninety percent of patients had heterozygous familial hypercholesterolaemia (heFH) and 75% had cardiovascular disease (CVD). One hundred forty patients were classified as very high risk because they had either cardiovascular disease (CVD) or heFH with an additional risk factor for whom a target <55 mg/dL is currently recommended. Of those very high risk patients, 105 (75%) were given PCSK9i due to failure to achieve LDL-C targets despite maximum LLT (high intensity statin at maximum tolerated dose + ezetimibe) while in the rest of cases the indication was statin intolerance. The mean reduction of LDL-C at 3 months was 56.2%. Among 105 very high risk patients (all had heFH), LDL-C below 55 mg/dL was achieved by 37.1% while the previously LDL-C target <70 mg/dL was achieved by 60% (Figure 1).
Conclusions
The new LDL-C target <55 mg/dL is achieved by <40% of very high risk patients with heFH despite receiving triple LLT, i.e. PCSK9i + statin + ezetimibe. This therapeutic gap suggests that there is still need for more effective LLT in very high risk heFH patients to maximize their clinical benefit.
Figure 1
Funding Acknowledgement
Type of funding source: None
Collapse
|
31
|
Liberopoulos E, Rizos C, Garoufi A, Kolovou G, Athyros V, Skoumas I, Kotsis V, Rallidis L, Tziomalos K, Skalides E, Attilakos A, Katsiki N, Koutagiar I, Antza C, Elisaf M. P5324Children with familial hypercholesterolemia: lipid profile, treatment and evaluation of different formulas for calculating low-density lipoprotein cholesterol: an analysis from the HELLAS-FH registry. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Introduction
There is limited data on cardiometabolic characteristics and treatment of underage patients with familial hypercholesterolemia (FH). Accurate estimation of low-density lipoprotein cholesterol is essential to tailor hypolipidemic treatment.
Purpose
To report lipid profile and current treatment of underage patients with FH in Greece as recorded in the HELLAS-FH registry. Also, to compare the Friedewald with the Martin/Hopkins equation, (which provides a customized estimation of VLDL-C) and the Dahlen's formula [(which adjusts the LDL-C measurements for the amount of cholesterol in Lp(a)].
Methods
Underage patients with FH were evaluated. Lipid profile, current treatment regimen as well as LDL-C levels as assessed with different formulas were evaluated.
Results
A total of 191 children were included (51.0% boys, 11.0±3.5 years old). Children at baseline had mean LDL-C as calculated by the Friedewald equation (LDL-CF) 233±65 mg/dL and median Lp(a) 15.3 (IQR 8–51) mg/dL. A total of 59.2% of subjects were receiving hypolipidemic treatment, mainly statins (29.4%) and sterols/stanols (25.5%). Children on hypolipidemic therapy had mean LDL-CF 183±98 mg/dL with 22.1% achieving an LDL-C≤130 mg/dL. When LDL-C was calculated based on the Martin-Hopkins equation (LDL-CM/H) respective values were 180±58 mg/dL and 24.8%. When LDL-C was corrected for Lp(a) [= LDL-CM/H − (Lp(a) * 0.30)], LDL-C was 174±105 mg/dL with 33.3% of patients within the LDL-C target.
Conclusions
Nearly two-thirds of children were receiving some kind of hypolipidemic treatment at the time of registration. For those on treatment, LDL-C goal is achieved by one in five, which rises to 1 in 3 when LDL-C is corrected for Lp(a) levels.
Collapse
|
32
|
Liberopoulos E, Rizos C, Skoumas I, Tziomalos K, Rallidis L, Kotsis V, Athyros V, Skalides E, Kolovou G, Garoufi A, Koutagiar I, Papagianni M, Kiouri E, Antza C, Elisaf M. P5321The association of Lp(a) levels and cardiovascular disease in adult patients with familial hypercholesterolemia: analysis from the HELLAS-FH registry. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Introduction
Familial hypercholesterolemia (FH) as well as elevated Lp(a) levels are both associated with increased cardiovascular disease (CVD) risk. There are limited data on the association of Lp(a) levels with CVD in FH Patients.
Purpose
To evaluate the association between Lp(a) levels and CVD in adult FH patients included in the HELLAS-FH registry in Greece.
Methods
Adult patients with FH and measured Lp(a) levels were included in this analysis. Demographics, CVD prevalence and lipid profile were evaluated.
Results
A total of 337 patients were evaluated (46% male, 48.3±15.4 years old). The median [IQR] of Lp(a) at baseline was 22.6 (9.7–56.2) mg/dL. Patients were categorized into 4 different groups according to the Lp(a) levels quartiles. There was no gender or age difference between the 4 groups. Moreover, all groups had similar smoking status, hypertension, body mass index and type 2 diabetes prevalence. There was no significant difference between groups regarding baseline and on treatment lipid profile. We observed a significant positive association between Lp(a) quartile and coronary artery disease (CAD) prevalence (p=0.004). Patients in the highest vs lowest quartile had greater CAD prevalence (21.7% vs 7%, p=0.006). No association was observed between Lp(a) quartile and the prevalence of cerebrovascular disease or peripheral artery disease.
Conclusions
Elevated Lp(a) levels have a positive correlation with CAD in patients with FH.
Collapse
|
33
|
Fountas E, Diakoumakou O, Kolovou V, Stratakis S, Zacharis E, Liberopoulos E, Matsouka F, Tsoutsinos A, Mastorakou I, Katsikas T, Mavrogeni S, Hatzigeorgiou G, Kolovou G. P5365Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolemia phenotype. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0330] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
The majority of patients with homozygous familial hypercholesterolemia (HoFH) phenotype are treated additionally to lipid lowering (LL) drugs (statin + ezetimibe ± colesevelam) with lipoprotein apheresis (LA) sessions. The aim of this study was to evaluate the effect of microsomal triglyceride transfer protein inhibitor (lomitapide) in HoFH patients.
Patients and methods
In 12 HoFH patients treated with LL drugs ± biweekly LA sessions (9 patients) the 5–40 mg daily of lomitapide was added. Lipid profile [total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), triglycerides (TG) and high density lipoprotein cholesterol (HDL-C)] before (LL drugs ± LA) and after lomitapide treatment were evaluated.
Results
The follow-up period of lomitapide treatment for 12 patients was 3–24 months (13.8±7.9). The median baseline LDL-C levels was 1000 mg/dL (339–1150). During LL drug therapy, patients showed a median LDL-C level of 383.5 mg/dL (Range: 214–866 mg/dL) and with LL drugs + Time-averaged levels (CAVG) the median was 288.1 mg/dL (Range: 183.69–716.65 mg/dL). The addition of lomitapide at the average dosage of 21.4 mg/day lowered LDL-C levels by 56.8% comparing to LL drugs alone therapy [mean reduction 262.12, 95% CI (105.53, 418.71), p=0.005] and by 54% [mean reduction −182.89, 95% CI (−342.35, −23.43), p=0.031] comparing to LL drugs + LA (CAVG). The CAVG of LDL-C in LL drugs + LA patients compared with LL drugs + lomitapide was 54% in favour of lomitapide (p=0.031). After lomitapide administration to LL drugs + LA treatment, 78% patients discontinued LA and 2 patients reduced their LA frequency by 50%. During follow-up, 2 patients (16.6%) reported side effects (transient diarrhea, 1 patient had liver transaminase >5× ULN and had to decrease dose of lomitapide). Two patients stopped lomitapide due to diet and alcohol restrictions.
Median and ranges of lipid and lipoprotein values before any intervention, after LL drugs, LL drugs plus LA, LL drugs plus LA (CAVG) and LL drugs plus lomitapide Total Cholesterol LDL-C HDL-C Triglycerides Before any intervention 1000 (339–1150) 900 (245–1070) 34.5 (25–50) 125 (87–314) After LL drugs 434 (278–915) 383.5 (214–866) 36 (27–51) 113 (62–198) LL drugs + LA (CAVG) 336.13 (248.57–784.16) 288.07 (183.69–716.65) 42.81 (25.84–46.68) 105.09 (55.79–166.68) LL drugs + Lomitapide 228.5 (118–554) 173.5 (74–515) 37.5 (29–50) 83.5 (23–316)
LDL graph
Conclusions
Treatment with lomitapide in HoFH patients has beneficial effect with constant decrease of LDL-C by 57% compared with classical LL therapy and by 54% compared with classical LL therapy and CAVG and seems to be with good safety profile. Although, in some cases the hybrid (all availably drug treatment and LA) therapy may be needed.
Collapse
|
34
|
Barkas F, Elisaf M, Dimitriou T, Liamis G, Rizos E, Liberopoulos E. Distance To Targets Of Low-Density Lipoprotein Cholesterol And Eligibility For Treatment With Pcsk9 Inhibitors In Patients At High Cardiovascular Risk. Atherosclerosis 2019. [DOI: 10.1016/j.atherosclerosis.2019.06.561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
35
|
Rizos C, Garoufi A, Elisaf M, Kolovou G, Athyros V, Skoumas I, Kotsis V, Rallidis L, Tziomalos K, Skalides E, Attilakos A, Katsiki N, Koutagiar I, Antza C, Kiouri E, Papagianni M, Loulakakis M, Liberopoulos E. Children With Familial Hypercholesterolemia: Cardiometabolic Profile Data From The Hellas-Fh Registry. Atherosclerosis 2019. [DOI: 10.1016/j.atherosclerosis.2019.06.640] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
36
|
Rizos C, Elisaf M, Skoumas I, Tziomalos K, Rallidis L, Kotsis V, Athyros V, Skalides E, Kolovou G, Garoufi A, Koutagiar I, Papagianni M, Kiouri E, Antza C, Katsiki N, Zacharis E, Attilakos A, Liberopoulos E. Cardiovascular Disease And Lp(A) Levels In Adult Patients With Familial Hydrocholesterolemia. Atherosclerosis 2019. [DOI: 10.1016/j.atherosclerosis.2019.06.641] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
37
|
Rizos C, Elisaf M, Skoumas I, Tziomalos K, Rallidis L, Kotsis V, Athyros V, Skalides E, Kolovou G, Garoufi A, Florentin M, Koutagiar I, Papagianni M, Kiouri E, Antza C, Katsiki N, Zacharis E, Attilakos A, Liberopoulos E. Adults With Familial Hydrocholesterolemia: Latest Update On Cardiometabolic Profile From The Hellas-Fh Registry. Atherosclerosis 2019. [DOI: 10.1016/j.atherosclerosis.2019.06.639] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
38
|
Barkas F, Elisaf M, Filippatos T, Ntekouan SF, Sakkas N, Liberopoulos E. Lipid And Glycemic Profile Of Overweight And Obese Patients. Atherosclerosis 2019. [DOI: 10.1016/j.atherosclerosis.2019.06.395] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
39
|
Barkas F, Elisaf M, Liberopoulos E, Klouras E, Kei A, Liontos A, Megapanou E, Lamouri C, Rizos E. Non-alcoholic fatty liver disease and its association with incident diabetes in statin-treated individuals. Atherosclerosis 2018. [DOI: 10.1016/j.atherosclerosis.2018.06.603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
40
|
Rizos C, Barkas F, Athyros V, Antza C, Attilakos A, Elisaf M, Zacharis E, Rallidis L, Kiouri E, Kolovou G, Loulakakis M, Boufidou A, Skoumas I, Liberopoulos E. Carbohydrate metabolism in patients with familial hypercholesterolemia: Data from the HELLAS-FH registry. Atherosclerosis 2018. [DOI: 10.1016/j.atherosclerosis.2018.06.533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
41
|
Barkas F, Filippas-Ntekouan S, Liberopoulos E, Christopoulou E, Pantazi A, Tzavella E, Elisaf M, Liamis G. Clinical application of PCSK9 inhibitors in a specialized lipid clinic. Atherosclerosis 2018. [DOI: 10.1016/j.atherosclerosis.2018.06.751] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
42
|
Angouridis A, Georgoula M, Tellis C, Filippatos T, Tselepis A, Liberopoulos E, Elisaf M. Serum PCSK9 levels are increased in obese subjects and negatively correlated with a mediterranean diet score. Atherosclerosis 2018. [DOI: 10.1016/j.atherosclerosis.2018.06.800] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
43
|
Barkas F, Pappa E, Liberopoulos E, Filippatos T, Florentin M, Christopoulou F, Elisaf M, Liamis G. Lipid target attainment in a specialized lipid clinic. Atherosclerosis 2018. [DOI: 10.1016/j.atherosclerosis.2018.06.251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
44
|
Rizos C, Athyros V, Antza C, Attilakos A, Elisaf M, Zacharis E, Rallidis L, Katsiki N, KiourI E, Kolovou G, Loulakakis M, Boufidou A, Skoumas I, Florentin M, Liberopoulos E. The achievement of the low-density lipoprotein cholesterol target in subjects with familial hypercholesterolemia: The role of PCSK9 inhibitors. Atherosclerosis 2018. [DOI: 10.1016/j.atherosclerosis.2018.06.534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
45
|
Barkas F, Elisaf M, Liberopoulos E, Rizos C, Dimitriou T, Sferopoulos D, Rizos E. Atherogenic dyslipidemia increased the risk of incident diabetes in statin-treated individuals. Atherosclerosis 2018. [DOI: 10.1016/j.atherosclerosis.2018.06.602] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
46
|
Barkas F, Klouras E, Dimitriou T, Liamis G, Elisaf M, Liberopoulos E. Incidence of cardiovascular disease among individuals with and without familial hypercholesterolemia attending a lipid clinic. Atherosclerosis 2016. [DOI: 10.1016/j.atherosclerosis.2016.07.376] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
47
|
Barkas F, Klouras E, Dimitriou T, Liamis G, Liberopoulos E, Elisaf M. Lipid-lowering therapy and target attainment among hypelipidemic individuals with or without familial hypercholesterolemia: Evidence from a lipid clinic. Atherosclerosis 2016. [DOI: 10.1016/j.atherosclerosis.2016.07.375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
48
|
Barkas F, Klouras E, Dimitriou T, Elisaf M, Liberopoulos E. Statin escape phenomenon: Does it really exist? Evidence from a lipid clinic. Atherosclerosis 2016. [DOI: 10.1016/j.atherosclerosis.2016.07.411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
49
|
Barkas F, Elisaf M, Rizos CV, Klouras E, Kostapanos MS, Liberopoulos E. Proton pump inhibitors and statins: a possible interaction that favors low-density lipoprotein cholesterol reduction? Hippokratia 2015; 19:332-337. [PMID: 27688698 PMCID: PMC5033144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
BACKGROUND Proton pump inhibitors (PPIs) might influence the metabolism of cholesterol and statins in the liver. AIM The impact of PPIs on low-density lipoprotein cholesterol (LDL-C) levels in statin-treated patients. METHODS Retrospective observational study including consecutive statin-treated individuals followed for ≥3 years in a university hospital lipid clinic. Demographic characteristics as well as clinical and laboratory data were recorded at baseline and the most recent visit. High, moderate and low-intensity statin therapy was defined according to the expected LDL-C reduction (≥50%, 30-50%, and <30%, respectively). We compared the LDL-C reduction in subjects receiving statin + PPI with those on statin alone and assessed the overall effect of PPI administration on LDL-C lowering. RESULTS Of 648 statin-treated subjects, 7% were also taking a PPI. There was no difference between PPI vs. non-PPI group regarding baseline characteristics and intensity of lipid-lowering therapy. Stepwise linear regression analysis showed that PPI use was significantly associated with LDL-C reduction (b =0.104, p =0.005) along with baseline LDL-C levels (b =0.482, p <0.001), treatment with ezetimibe (b =0.198, p <0.001), presence of diabetes (b =0.168, p <0.001), compliance with treatment (b =0.205, p <0.001), intensity of statin treatment (b =0.101, p =0.005) and cardiovascular risk (b =0.082, p =0.049). Subjects receiving statin + PPI had a higher LDL-C reduction by 6.4% compared with those taking a statin alone (fully adjusted p =0.005). CONCLUSIONS PPIs may modestly boost the statin-mediated LDL-C reduction. This effect should be confirmed by prospective clinical studies. Hippokratia 2015; 19 (4): 332-337.
Collapse
|
50
|
Barkas F, Liberopoulos E, Kostapanos M, Rizos C, Klouras E, Elisaf M. Proton pump inhibitors and statins: a combination that favors ldl-c reduction? Atherosclerosis 2015. [DOI: 10.1016/j.atherosclerosis.2015.04.973] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|